Dossier · Private startup · 1 independent source
Immunai
Last updated: Jul 31, 2026
Immunai is a privately held computational-immunology company that combines single-cell multi-omics, the AMICA immune-cell data foundation, machine learning, and functional validation to help biopharma teams discover targets, evaluate candidates, and make better clinical-development decisions.
Visit WebsiteCompany Overview
Immunai's product is an end-to-end immune-intelligence workflow rather than a standalone analytics package. The company generates high-dimensional data from clinical and preclinical samples, harmonizes it with AMICA (Annotated Multi-omic Immune Cell Atlas), computes immune features associated with disease and treatment response, tests selected hypotheses through functional genomics, and returns recommendations to a drug-development team. Public materials describe whole-transcriptome and surface-protein profiling, T-cell and B-cell receptor sequencing, clinical metadata integration, cell annotation, and machine-learning models that connect cell states to outcomes. The newer AMICA-OS positioning extends that foundation toward an operating layer for repeated pharma decisions, while the earlier ImmunoDynamics Engine remains a useful description of the modeling approach.
The commercial customer is primarily a biopharmaceutical company with an expensive, uncertain pipeline and a need for better biological evidence. Immunai describes three decision points: target discovery, preclinical evaluation, and clinical-trial optimization. In practice, value depends on turning patient-derived samples and disease context into actionable hypotheses: which targets are associated with a disease state, which patient subgroups are likely to respond, how a mechanism compares with standard of care, and where toxicity or resistance may emerge. The company says it works across oncology and inflammatory disease, with public examples involving AstraZeneca's inflammatory-bowel-disease and oncology programs and Teva's vitiligo and IL-15 work. Recent company communications also describe an expanded AstraZeneca collaboration through 2027 and a Boehringer Ingelheim collaboration on T-cell targets; these are useful traction signals, but they do not by themselves prove clinical success, recurring software revenue, or validated improvement in approval rates.
Immunai's defensibility thesis is the combination of immune-specific data curation, wet-lab capability, disease and treatment annotations, and a workflow that can close the loop between model output and experimental validation. The official company page says AMICA was strengthened through the acquisitions of Dropprint Genomics and Nebion, and reports a multidisciplinary global team with more than 80 PhDs. LinkedIn lists the company in the 51–200 employee band and shows 176 employees, so the prior 201–500 estimate appears stale. The competitive field includes Owkin, insitro, Recursion, Cellarity, Nucleai, and internal pharma computational-biology groups. Alternatives can combine public single-cell datasets, contract research organizations, general-purpose foundation models, and in-house translational teams; Immunai must therefore demonstrate that its proprietary harmonization and validation produce decisions that customers cannot obtain more cheaply elsewhere.
The company remains a private, mid-stage startup: the last clearly disclosed financing is its 2021 Series B, while its current website emphasizes continuing partnerships and platform development rather than an announced IPO or later financing. The main diligence questions are the age of the financing information, cash runway and revenue mix, repeatability of partner expansions, ownership and permitted use of patient-level data, reproducibility of target-ranking claims, and whether functional validation translates into differentiated clinical outcomes. National-security relevance is limited. Immune profiling could support broad biodefense, vaccine, or pathogen-response research, but no public evidence reviewed here shows Immunai selling to defense customers, developing pathogen-specific capabilities, or operating a security mission. Its strategic relevance is therefore strongest as an advanced civilian biotech-data platform with optional, indirect resilience value—not as a conventional dual-use or defense investment.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Immunai is a credible deep-tech biotech priority signal because it combines a differentiated immune-data asset, computational biology, wet-lab validation, and public evidence of continuing work with large pharmaceutical partners. The opportunity is strongest as a civilian drug-discovery platform: the addressable pharma problem is valuable, but commercial proof remains difficult to assess because the last clearly disclosed financing is the 2021 Series B and public materials do not establish revenue, milestone economics, or clinical-outcome uplift. The legacy strategically relevant flag is therefore supported by strategic fit and technical depth, not an investment recommendation; dual-use contribution is modest.
Strategic Value to U.S.-Israel Alliance
Immunai could provide strategic value by improving how biopharma companies select targets, interpret response heterogeneity, and allocate clinical-development resources in immune-mediated disease. Its data curation and validation loop may be more difficult to replicate than a generic model, while partnerships can create proprietary feedback and new annotated cohorts. The value case depends on customer retention, rights to use and enrich patient data, measurable influence on pipeline decisions, and conversion of collaborations into durable commercial revenue. National-security value is indirect and should not be counted as a core thesis.
Key Technologies
- Single-cell multi-omics: transcriptome, surface proteome, TCR/BCR repertoire, and clinical sample profiling
- AMICA harmonized immune-cell atlas with disease and clinical metadata integration
- AMICA-OS platform for immune-data workflows and pharma decision support
- ImmunoDynamics Engine and machine-learning models linking immune features to treatment response
- Automated cell annotation, data harmonization, and high-dimensional representation learning
- Functional genomics and wet-lab perturbation used to validate computational hypotheses
Use Cases & Applications
- Target discovery for oncology, inflammatory bowel disease, autoimmune, and other immune-mediated indications
- Prioritization of preclinical drug candidates and disease-relevant mechanisms
- Biomarker discovery and patient-response segmentation for clinical trials
- Mechanism-of-action and resistance analysis for antibodies and other therapeutics
- Cross-study integration of clinical and preclinical immune datasets
- Research collaborations that add anonymized patient cohorts to immune-disease atlases
- Indirect biodefense or vaccine-response research, only as a prospective adjacency requiring separate validation
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 6 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- immunai.com Public source used for profile verification.
- immunai.com Public source used for profile verification.
- immunai.com Public source used for profile verification.
- immunai.com Public source used for profile verification.
- LinkedIn company page Public source used for profile verification.
- techcrunch.com Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the AI & Data Platforms sector page for market context, related subcategories, and other Israeli companies in this part of the database.